The effectiveness of aerobic training, cognitive behavioural therapy, and energy conservation management in treating MS-related fatigue: the design of the TREFAMS-ACE programme

Heleen Beckerman, Lyan Jm Blikman, Martin Heine, Arjan Malekzadeh, Charlotte E Teunissen, Johannes Bj Bussmann, Gert Kwakkel, Jetty van Meeteren, Vincent de Groot, TREFAMS-ACE study group, V de Groot, H Beckerman, A Malekzadeh, M Looijmans, S A Sanches, J Dekker, E H Collette, B W van Oosten, C E Teunissen, M A Blankenstein, I C J M Eijssen, M Rietberg, M Heine, I G L van de Port, E Lindeman, G Kwakkel, L J M Blikman, J van Meeteren, J B J Bussmann, H J Stam, R Q Hintzen, H G A Hacking, S T F M Frequin, E Hoogervorst, B A de Jong, J H Knoop, G Bleijenberg, F A J de Laat, G J Aarts, Heleen Beckerman, Lyan Jm Blikman, Martin Heine, Arjan Malekzadeh, Charlotte E Teunissen, Johannes Bj Bussmann, Gert Kwakkel, Jetty van Meeteren, Vincent de Groot, TREFAMS-ACE study group, V de Groot, H Beckerman, A Malekzadeh, M Looijmans, S A Sanches, J Dekker, E H Collette, B W van Oosten, C E Teunissen, M A Blankenstein, I C J M Eijssen, M Rietberg, M Heine, I G L van de Port, E Lindeman, G Kwakkel, L J M Blikman, J van Meeteren, J B J Bussmann, H J Stam, R Q Hintzen, H G A Hacking, S T F M Frequin, E Hoogervorst, B A de Jong, J H Knoop, G Bleijenberg, F A J de Laat, G J Aarts

Abstract

Background: TREFAMS is an acronym for TReating FAtigue in Multiple Sclerosis, while ACE refers to the rehabilitation treatment methods under study, that is, Aerobic training, Cognitive behavioural therapy, and Energy conservation management. The TREFAMS-ACE research programme consists of four studies and has two main objectives: (1) to assess the effectiveness of three different rehabilitation treatment strategies in reducing fatigue and improving societal participation in patients with MS; and (2) to study the neurobiological mechanisms of action that underlie treatment effects and MS-related fatigue in general.

Methods/design: Ambulatory patients (n = 270) suffering from MS-related fatigue will be recruited to three single-blinded randomised clinical trials (RCTs). In each RCT, 90 patients will be randomly allocated to the trial-specific intervention or to a low-intensity intervention that is the same for all RCTs. This low-intensity intervention consists of three individual consultations with a specialised MS-nurse. The trial-specific interventions are Aerobic Training, Cognitive Behavioural Therapy, and Energy Conservation Management. These interventions consist of 12 individual therapist-supervised sessions with additional intervention-specific home exercises. The therapy period lasts 16 weeks. All RCTs have the same design and the same primary outcome measures: fatigue - measured with the Checklist Individual Strength, and participation - measured with the Impact on Participation and Autonomy questionnaire. Outcomes will be assessed 1 week prior to, and at 0, 8, 16, 26 and 52 weeks after randomisation. The assessors will be blinded to allocation. Pro- and anti-inflammatory cytokines in serum, salivary cortisol, physical fitness, physical activity, coping, self-efficacy, illness cognitions and other determinants will be longitudinally measured in order to study the neurobiological mechanisms of action.

Discussion: The TREFAMS-ACE programme is unique in its aim to assess the effectiveness of three rehabilitation treatments. The programme will provide important insights regarding the most effective treatment for MS-related fatigue and the mechanisms that underlie treatment response. A major strength of the programme is that the design involves three almost identical RCTs, enabling a close comparison of the treatment strategies and a strong overall meta-analysis. The results will also support clinical practice guidelines for the treatment of MS-related fatigue.

Trial registrations: Current Controlled Trials ISRCTN69520623, ISRCTN58583714, and ISRCTN82353628.

Figures

Figure 1
Figure 1
The design of the TREFAMS-ACE programme.

References

    1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;343:938–952. doi: 10.1056/NEJM200009283431307.
    1. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:1502–1517. doi: 10.1016/S0140-6736(08)61620-7.
    1. Koch-Henriksen N, Sorensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol. 2010;9:520–532. doi: 10.1016/S1474-4422(10)70064-8.
    1. De Groot V, Beckerman H, Twisk JW, Uitdehaag BM, Hintzen RQ, Minneboo A, Lankhorst GJ, Polman CH, Bouter LM. Vitality, perceived social support and disease activity determine the performance of social roles in recently diagnosed multiple sclerosis: a longitudinal analysis. J Rehabil Med. 2008;40:151–157. doi: 10.2340/16501977-0145.
    1. Kos D, Kerckhofs E, Nagels G, D’Hooghe MB, Ilsbroukx S. Origin of fatigue in multiple sclerosis: review of the literature. Neurorehabil Neural Repair. 2008;22:91–100.
    1. Stuke K, Flachenecker P, Zettl UK, Elias WG, Freidel M, Haas J, Pitschnau-Michel D, Schimrigk S, Rieckmann P. Symptomatology of MS: results from the German MS registry. J Neurol. 2009;256:1932–1935. doi: 10.1007/s00415-009-5257-5.
    1. DeLuca J. In: Fatigue as a window to the brain. DeLuca J, editor. Cambridge, MA: The MIT Press; 2005. Fatigue: its definition, its study, and its future.
    1. Multiple Sclerosis Council for Clinical Practice Guidelines. Fatigue and Multiple Sclerosis: evidence-based management strategies for fatigue in multiple sclerosis. Washington, DC: Paralyzed Veterans of America; 1998.
    1. Chaudhuri A, Behan PO. Fatigue in neurological disorders. Lancet. 2004;363:978–988. doi: 10.1016/S0140-6736(04)15794-2.
    1. Krupp LB, Christodoulou C, Schombert H. In: Fatigue as a window to the brain. DeLuca J, editor. Cambridge, MA: The MIT Press; 2005. Multiple sclerosis and fatigue.
    1. Sternberg Z. Sympathetic nervous system dysfunction in multiple sclerosis, linking neurodegeneration to a reduced response to therapy. Curr Pharm Des. 2012;18:1635–1644. doi: 10.2174/138161212799958639.
    1. Huitinga I, van der Cammen M, Salm L, Erkut Z, van Dam A, Tilders F, Swaab D. IL-1beta immunoreactive neurons in the human hypothalamus: reduced numbers in multiple sclerosis. J Neuroimmunol. 2000;107:8–20. doi: 10.1016/S0165-5728(00)00248-4.
    1. Gottschalk M, Kümpfel T, Flachenecker P, Uhr M, Trenkwalder C, Holsboer F, Weber F. Fatigue and regulation of the hypothalamo-pituitary-adrenal axis in multiple sclerosis. Arch Neurol. 2005;62:277–280. doi: 10.1001/archneur.62.2.277.
    1. Induruwa I, Constantinescu CS, Gran B. Fatigue in multiple sclerosis - a brief review. J Neurol Sci. 2012;323:9–15. doi: 10.1016/j.jns.2012.08.007.
    1. Amato MP, Portaccio E. Management options in multiple sclerosis-associated fatigue. Expert Opin Pharmacother. 2012;13:207–216. doi: 10.1517/14656566.2012.647767.
    1. Dodd KJ, Taylor NF, Shields N, Prasad D, McDonald E, Gillon A. Progressive resistance training did not improve walking but can improve muscle performance, quality of life and fatigue in adults with multiple sclerosis: a randomized controlled trial. Mult Scler. 2011;17:1362–1374. doi: 10.1177/1352458511409084.
    1. Dalgas U, Stenager E, Jakobsen J, Petersen T, Hansen HJ, Knudsen C, Overgaard K, Ingemann-Hansen T. Fatigue, mood and quality of life improve in MS patients after progressive resistance training. Mult Scler. 2010;16:480–490. doi: 10.1177/1352458509360040.
    1. Cakt BD, Nacir B, Genç H, Saraçoğlu M, Karagöz A, Erdem HR, Ergün U. Cycling progressive resistance training for people with multiple sclerosis: a randomized controlled study. Am J Phys Med Rehabil. 2010;89:446–457. doi: 10.1097/PHM.0b013e3181d3e71f.
    1. Petajan JH, Gappmaier E, White AT, Spencer MK, Mino L, Hicks RW. Impact of aerobic training on fitness and quality of life in multiple sclerosis. Ann Neurol. 1996;39:432–441. doi: 10.1002/ana.410390405.
    1. Andreasen AK, Stenager E, Dalgas U. The effect of exercise therapy on fatigue in multiple sclerosis. Mult Scler. 2011;17:1041–1054. doi: 10.1177/1352458511401120.
    1. Rietberg MB, Brooks D, Uitdehaag BM, Kwakkel G. Exercise therapy for multiple sclerosis. Cochrane Database Syst Rev. 2005;1 CD003980.
    1. Hayes HA, Gappmaier E, LaStayo PC. Effects of high-intensity resistance training on strength, mobility, balance, and fatigue in individuals with multiple sclerosis: a randomized controlled trial. J Neurol Phys Ther. 2011;35:2–10. doi: 10.1097/NPT.0b013e31820b5a9d.
    1. Van Kessel K, Moss-Morris R, Willoughby E, Chalder T, Johnson MH, Robinson E. A randomized controlled trial of cognitive behavior therapy for multiple sclerosis fatigue. Psychosom Med. 2008;70:205–213. doi: 10.1097/PSY.0b013e3181643065.
    1. Mathiowetz VG, Finlayson ML, Matuska KM, Chen HY, Luo P. Randomized controlled trial of an energy conservation course for persons with multiple sclerosis. Mult Scler. 2005;11:592–601. doi: 10.1191/1352458505ms1198oa.
    1. Mathiowetz VG, Matuska KM, Finlayson ML, Luo P, Chen HY. One-year follow-up to a randomized controlled trial of an energy conservation course for persons with multiple sclerosis. Int J Rehabil Res. 2007;30:305–313. doi: 10.1097/MRR.0b013e3282f14434.
    1. Finlayson M, Preissner K, Cho C, Plow M. Randomized trial of a teleconference-delivered fatigue management program for people with multiple sclerosis. Mult Scler. 2011;17:1130–1140. doi: 10.1177/1352458511404272.
    1. Neill J, Belan I, Ried K. Effectiveness of non-pharmacological interventions for fatigue in adults with multiple sclerosis, rheumatoid arthritis, or systemic lupus erythematosus: a systematic review. J Adv Nurs. 2006;56:617–635. doi: 10.1111/j.1365-2648.2006.04054.x. Erratum in: J Adv Nurs 2007, 57:225.
    1. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P. CONSORT Group. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Ann Intern Med. 2008;148:295–309. doi: 10.7326/0003-4819-148-4-200802190-00008.
    1. Heine M, Rietberg MB, Van Wegen EEH, Port IGL Van D, Kwakkel G. Exercise therapy for fatigue in multiple sclerosis. Cochrane Database Syst Rev. 2012;7:CD009956.
    1. Blikman LJ, Huisstede BM, Kooijmans H, Stam HJ, Bussmann JBJ, Van Meeteren J. Effectiveness of energy conservation treatment in reducing fatigue in multiple sclerosis. A systematic review and meta-analysis. Arch Phys Med Rehabil. 2013;94:1360–1376. doi: 10.1016/j.apmr.2013.01.025.
    1. Gold SM, Krüger S, Ziegler KJ, Krieger T, Schulz KH, Otte C, Heesen C. Endocrine and immune substrates of depressive symptoms and fatigue in multiple sclerosis patients with comorbid major depression. J Neurol Neurosurg Psychiatr. 2011;82:814–818. doi: 10.1136/jnnp.2010.230029.
    1. Heesen C, Nawrath L, Reich C, Bauer N, Schulz KH, Gold SM. Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour? J Neurol Neurosurg Psychiatr. 2006;77:34–39. doi: 10.1136/jnnp.2005.065805.
    1. Flachenecker P, Bihler I. Cytokine mRNA expression in patients with MS and fatigue. Mult Scler. 2004;10:165–169. doi: 10.1191/1352458504ms991oa.
    1. Stranahan AM, Lee K, Mattson MP. Central mechanisms of HPA axis regulation by voluntary exercise. Neuromolecular Med. 2008;10:118–127. doi: 10.1007/s12017-008-8027-0.
    1. Castellano V, Patel DI, White LJ. Cytokine responses to acute and chronic exercise in multiple sclerosis. J Appl Physiol. 2008;104:1697–1702. doi: 10.1152/japplphysiol.00954.2007.
    1. Skerrett TN, Moss-Morris R. Fatigue and social impairment in multiple sclerosis: the role of patients' cognitive and behavioral responses to their symptoms. J Psychosom Res. 2006;61:587–593. doi: 10.1016/j.jpsychores.2006.04.018.
    1. Packer T, Brink N, Sauriol A. Managing fatigue: a six-week course for energy conservation. Tucson, AZ: Therapy Skill Builders; 1995.
    1. Fischer A, Heesen C, Gold SM. Biological outcome measurements for behavioral interventions in multiple sclerosis. Ther Adv Neurol Disord. 2011;4:217–229. doi: 10.1177/1756285611405252.
    1. Malekzadeh A, de Groot V, Beckerman H, van Oosten BW, Blankenstein MA, Teunissen C. Challenges in multi-plex and mono-plex platforms for the discovery of inflammatory profiles in neurodegenerative diseases. Methods. 2012;56:508–513. doi: 10.1016/j.ymeth.2012.03.017.
    1. American College of Sports Medicine. ACSM’s guidelines for exercise testing and prescription. 8. Philadelphia, PA: Lippincott Williams & Wilkins; 2010.
    1. Voet NB, Bleijenberg G, Padberg GW, van Engelen BG, Geurts AC. Effect of aerobic exercise training and cognitive behavioural therapy on reduction of chronic fatigue in patients with facioscapulohumeral dystrophy: protocol of the FACTS-2-FSHD trial. BMC Neurol. 2010;10:56. doi: 10.1186/1471-2377-10-56.
    1. Koopman FS, Beelen A, Gerrits KH, Bleijenberg G, Abma TA, de Visser M, Nollet F. Exercise therapy and cognitive behavioural therapy to improve fatigue, daily activity performance and quality of life in postpoliomyelitis syndrome: the protocol of the FACTS-2-PPS trial. BMC Neurol. 2010;10:8. doi: 10.1186/1471-2377-10-8.
    1. Knoop H, Bleijenberg G. Cognitieve gedragstherapie voor chronische vermoeidheid bij MS patiënten. 2011. (Nijmeegs Kenniscentrum Chronische Vermoeidheid: Behandelprotocol. Nijmegen).
    1. Prins JB, Bleijenberg G, Bazelmans E, Elving LD, de Boo TM, Severens JL, van der Wilt GJ, Spinhoven P, van der Meer JW. Cognitive behaviour therapy for chronic fatigue syndrome: a multicentre randomised controlled trial. Lancet. 2001;357:841–847. doi: 10.1016/S0140-6736(00)04198-2.
    1. Huibers MJ, Beurskens AJ, Van Schayck CP, Bazelmans E, Metsemakers JF, Knottnerus JA, Bleijenberg G. Efficacy of cognitive-behavioural therapy by general practitioners for unexplained fatigue among employees: randomised controlled trial. Br J Psychiatr. 2004;184:240–246. doi: 10.1192/bjp.184.3.240.
    1. Stulemeijer M, De Jong LW, Fiselier TJ, Hoogveld SW, Bleijenberg G. Cognitive behaviour therapy for adolescents with chronic fatigue syndrome: randomised controlled trial. BMJ. 2005;330:14. doi: 10.1136/bmj.38301.587106.63. Erratum in: BMJ 2005, 330:820.
    1. Gielissen MF, Verhagen S, Witjes F, Bleijenberg G. Effects of cognitive behavior therapy in severely fatigued disease-free cancer patients compared with patients waiting for cognitive behavior therapy: a randomized controlled trial. J Clin Oncol. 2006;24:4882–4887. doi: 10.1200/JCO.2006.06.8270.
    1. Goedendorp MM, Peters ME, Gielissen MF, Witjes JA, Leer JW, Verhagen CA, Bleijenberg G. Is increasing physical activity necessary to diminish fatigue during cancer treatment? comparing cognitive behavior therapy and a brief nursing intervention with usual care in a multicenter randomized controlled trial. Oncologist. 2010;15:1122–1132. doi: 10.1634/theoncologist.2010-0092.
    1. Jacobs HM, Luttik A, Touw-Otten FW, De Melker RA. [The sickness impact profile; results of an evaluation study of the Dutch version] Ned Tijdschr Geneeskd. 1990;134:1950–1954.
    1. Van der Ploeg E, Mooren TT, Kleber RJ, van der Velden PG, Brom D. Construct validation of the Dutch version of the impact of event scale. Psychol Assess. 2004;16:16–26.
    1. Buchi S, Sensky T, Sharpe L, Timberlake N. Graphic representation of illness: a novel method of measuring patients’ perceptions of the impact of illness. Psychother Psychosom. 1998;67:222–225. doi: 10.1159/000012284.
    1. Evers AW, Kraaimaat FW, van Lankveld W, Jongen PJ, Jacobs JW, Bijlsma JW. Beyond unfavorable thinking: the illness cognition questionnaire for chronic diseases. J Consult Clin Psychol. 2001;69:1026–1036.
    1. Knoop H, van Kessel K, Moss-Morris R. Which cognitions and behaviours mediate the positive effect of cognitive behavioural therapy on fatigue in patients with multiple sclerosis? Psychol Med. 2012;42:205–213. doi: 10.1017/S0033291711000924.
    1. Dennison L, Moss-Morris R, Silber E, Galea I, Chalder T. Cognitive and behavioural correlates of different domains of psychological adjustment in early-stage multiple sclerosis. J Psychosom Res. 2010;69:353–361. doi: 10.1016/j.jpsychores.2010.04.009.
    1. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–370. doi: 10.1111/j.1600-0447.1983.tb09716.x.
    1. Herschbach P, Berg P, Dankert A, Duran G, Engst-Hastreiter U, Waadt S, Keller M, Ukat R, Henrich G. Fear of progression in chronic diseases: psychometric properties of the fear of progression questionnaire. J Psychosom Res. 2005;58:505–511. doi: 10.1016/j.jpsychores.2005.02.007.
    1. Kwakkenbos L, van den Hoogen FH, Custers J, Prins J, Vonk MC, van Lankveld WG, Becker ES, van den Ende CH. Validity of the fear of progression questionnaire-short form in patients with systemic sclerosis. Arthritis Care Res (Hoboken) 2012;64:930–934. doi: 10.1002/acr.21618.
    1. Jacobsen PB, Azzarello LM, Hann DM. Relation of catastrophizing to fatigue severity in women with breast cancer. Canc Res Ther Contr. 1999;8:155–164.
    1. Jacobsen PB, Andrykowski MA, Thors CL. Relationship of catastrophizing to fatigue among women receiving treatment for breast cancer. J Consult Clin Psychol. 2004;72:355–361.
    1. Ray C, Weir W, Stewart D, Miller P, Hyde G. Ways of coping with chronic fatigue syndrome: development of an illness management questionnaire. Soc Sci Med. 1993;37:385–391. doi: 10.1016/0277-9536(93)90268-9.
    1. Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R, Sprangers MA, te Velde A, Verrips E. Translation, validation, and norming of the Dutch language version of the SF-36 health survey in community and chronic disease populations. J Clin Epidemiol. 1998;51:1055–1068. doi: 10.1016/S0895-4356(98)00097-3.
    1. Vercoulen JH, Hommes OR, Swanink CM, Jongen PJ, Fennis JF, Galama JM, van der Meer JW, Bleijenberg G. The measurement of fatigue in patients with multiple sclerosis. a multidimensional comparison with patients with chronic fatigue syndrome and healthy subjects. Arch Neurol. 1996;53:642–649. doi: 10.1001/archneur.1996.00550070080014.
    1. Van Sonderen E. Sociale Steun Lijst-Interacties (SSL-I) en Sociale Steun Lijst -Discrepanties (SSL-D) Groningen: Noordelijk Centrum voor Gezondheidsvraagstukken; 1993.
    1. Sullivan MJL, Bishop SR, Pivik J. The pain catastrophizing scale: development and validation. Psychol Assess. 1995;7:532.
    1. Corry M, McKenna M, Duggan M. The role of the clinical nurse specialist in MS: a literature review. Br J Nurs. 2011;20:86–93.
    1. Beurskens AJ, Bultmann U, Kant I, Vercoulen JH, Bleijenberg G, Swaen GM. Fatigue among working people: validity of a questionnaire measure. Occup Environ Med. 2000;57:353–357. doi: 10.1136/oem.57.5.353.
    1. Rietberg MB, Van Wegen EE, Kwakkel G. Measuring fatigue in patients with multiple sclerosis: reproducibility, responsiveness and concurrent validity of three Dutch self-report questionnaires. Disabil Rehabil. 2010;32:1870–1876. doi: 10.3109/09638281003734458. Erratum in: Disabil Rehabil 2011, 33:1298.
    1. Elbers RG, Rietberg MB, van Wegen EE, Verhoef J, Kramer SF, Terwee CB, Kwakkel G. Self-report fatigue questionnaires in multiple sclerosis, Parkinson’s disease and stroke: a systematic review of measurement properties. Qual Life Res. 2012;21:925–944. doi: 10.1007/s11136-011-0009-2.
    1. Cardol M, Beelen A, van den Bos GA, de Jong BA, de Groot IJ, de Haan RJ. Responsiveness of the impact on participation and autonomy questionnaire. Arch Phys Med Rehabil. 2002;83:1524–1529. doi: 10.1053/apmr.2002.35099.
    1. Magasi S, Post MW. A comparative review of contemporary participation measures' psychometric properties and content coverage. Arch Phys Med Rehabil. 2010;9:S17–S28.
    1. Kos D, Kerckhofs E, Nagels G, D’Hooghe BD, Duquet W, Duportail M, Ketelaer P. Assessing fatigue in multiple sclerosis: Dutch modified fatigue impact scale. Acta Neurol Belg. 2003;103:185–191.
    1. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46:1121–1123. doi: 10.1001/archneur.1989.00520460115022.
    1. Van Bennekom CA, Jelles F, Lankhorst GJ, Bouter LM. The Rehabilitation activities profile: a validation study of its use as a disability index with stroke patients. Arch Phys Med Rehabil. 1995;76:501–507. doi: 10.1016/S0003-9993(95)80502-8.
    1. Finlayson M, Preissner K, Cho C. Outcome moderators of a fatigue management program for people with multiple sclerosis. Am J Occup Ther. 2012;66:187–197. doi: 10.5014/ajot.2012.003160.
    1. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology. 1983;33:1444–1452. doi: 10.1212/WNL.33.11.1444.
    1. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc. 1968;16:622–626.
    1. De Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity. A critical review of available methods. J Clin Epidemiol. 2003;56:221–229. doi: 10.1016/S0895-4356(02)00585-1.
    1. Beatty WW, Goodkin DE. Screening for cognitive impairment in multiple sclerosis. an evaluation of the mini-mental state examination. Arch Neurol. 1990;47:297–301. doi: 10.1001/archneur.1990.00530030069018.
    1. Van der Ploeg HP, Streppel KR, van der Beek AJ, van der Woude LH, Vollenbroek-Hutten M, van Mechelen W. The physical activity scale for individuals with physical disabilities: test-retest reliability and comparison with an accelerometer. J Phys Act Health. 2007;4:96–100.
    1. Washburn RA, Zhu W, McAuley E, Frogley M, Figoni SF. The physical activity scale for individuals with physical disabilities: development and evaluation. Arch Phys Med Rehabil. 2002;83:193–200. doi: 10.1053/apmr.2002.27467.
    1. Fournier M, De Ridder D, Bensing J. Optimism and adaptation to chronic disease: the role of optimism in relation to self-care options of type 1 diabetes mellitus, rheumatoid arthritis and multiple sclerosis. Br J Health Psychol. 2002;7:409–432. doi: 10.1348/135910702320645390.
    1. Cohan SL, Jang KL, Stein MB. Confirmatory factor analysis of a short form of the coping inventory for stressful situations. J Clin Psychol. 2006;62:273–283. doi: 10.1002/jclp.20211.
    1. Schwarzer R, Jerusalem M. In: Measures in health psychology: A user’s portfolio. Weinman J, Wright S, Johnston M, editor. 1995. Generalized Self-Efficacy scale; pp. 35–37. (Windsor: Causal and control beliefs).
    1. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14:540–545.
    1. Broadbent E, Petrie KJ, Main J, Weinman J. The brief illness perception questionnaire. J Psychosom Res. 2006;60:631–637. doi: 10.1016/j.jpsychores.2005.10.020.
    1. Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M, Franciotta D, Frederiksen JL, Fleming JO, Furlan R, Hintzen RQ, Hughes SG, Johnson MH, Krasulova E, Kuhle J, Magnone MC, Rajda C, Rejdak K, Schmidt HK, van Pesch V, Waubant E, Wolf C, Giovannoni G, Hemmer B, Tumani H, Deisenhammer F. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology. 2009;73:1914–1922. doi: 10.1212/WNL.0b013e3181c47cc2.
    1. Mallik PS, Finlayson M, Mathiowetz V, Fogg L. Psychometric evaluation of the energy conservation strategies survey. Clin Rehabil. 2005;19:538–543. doi: 10.1191/0269215505cr789oa.
    1. Van der Werf SP, Jongen PJ, LA Nijeholt GJ, Barkhof F, Hommes OR, Bleijenberg G. Fatigue in multiple sclerosis: interrelations between fatigue complaints, cerebral MRI abnormalities and neurological disability. J Neurol Sci. 1998;160:164–170. doi: 10.1016/S0022-510X(98)00251-2.
    1. Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis. 2nd edition. Hoboken, NJ. Wiley Series in Probability and Statistics: John Wiley & Sons; 2011.
    1. Nicholas R, Rashid W. Multiple sclerosis. Clin Evid (Online) 2012. p. 1202.
    1. Tallner A, Waschbisch A, Wenny I, Schwab S, Hentschke C, Pfeifer K, Mäurer M. Multiple sclerosis relapses are not associated with exercise. Mult Scler. 2012;18:232–235. doi: 10.1177/1352458511415143.
    1. Sim I, Chan AW, Gülmezoglu AM, Evans T, Pang T. Clinical trial registration: transparency is the watchword. Lancet. 2006;367:1631–1633. doi: 10.1016/S0140-6736(06)68708-4.
    1. Milette K, Roseman M, Thombs BD. Transparency of outcome reporting and trial registration of randomized controlled trials in top psychosomatic and behavioral health journals: a systematic review. J Psychosom Res. 2011;70:205–217. doi: 10.1016/j.jpsychores.2010.09.015.
    1. Rosti-Otajärvi EM, Hämäläinen PI. Neuropsychological rehabilitation for multiple sclerosis. Cochrane Database Syst Rev. 2011;11 CD009131.
    1. Khan F, Turner-Stokes L, Ng L, Kilpatrick T. Multidisciplinary rehabilitation for adults with multiple sclerosis. Cochrane Database Syst Rev. 2007;2 CD006036.
    1. Golden SH, Wand GS, Malhotra S, Kamel I, Horton K. Reliability of hypothalamic-pituitary-adrenal axis assessment methods for use in population-based studies. Eur J Epidemiol. 2011;26:511–525. doi: 10.1007/s10654-011-9585-2.
    1. Abma TA, Broerse JE. Patient participation as dialogue: setting research agendas. Health Expect. 2010;13:160–173. doi: 10.1111/j.1369-7625.2009.00549.x.
    1. Siemonsma PC, Walker MF. Practical guidelines for independent assessment in randomized controlled trials (RCTs) of rehabilitation. Clin Rehabil. 1997;11:273–279. doi: 10.1177/026921559701100402.
    1. Boutron I, Guittet L, Estellat C, Moher D, Hróbjartsson A, Ravaud P. Reporting methods of blinding in randomized trials assessing nonpharmacological treatments. PLoS Med. 2007;4:e61. doi: 10.1371/journal.pmed.0040061.
    1. Kos D, Duportail M, D'hooghe M, Nagels G, Kerckhofs E. Multidisciplinary fatigue management programme in multiple sclerosis: a randomized clinical trial. Mult Scler. 2007;13:996–1003. doi: 10.1177/1352458507078392.
    1. Hugos CL, Copperman LF, Fuller BE, Yadav V, Lovera J, Bourdette DN. Clinical trial of a formal group fatigue program in multiple sclerosis. Mult Scler. 2010;16:724–732. doi: 10.1177/1352458510364536.
    1. Thomas PW, Thomas S, Kersten P, Jones R, Nock A, Slingsby V, Green C, Baker R, Galvin K, Hillier C. Multi-centre parallel arm randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based cognitive behavioural approach to managing fatigue in people with multiple sclerosis. BMC Neurol. 2010;10:43. doi: 10.1186/1471-2377-10-43.
    1. Anonymous. Conceptrichtlijn Diagnostiek, Behandeling en Functioneren bij Multiple Sclerose. Utrecht: CBO; 2011.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren